Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum.

Brain Behav Immun 2021 Jan 6;91:673-682. Epub 2020 Sep 6.

Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom. Electronic address:

Recent evidence suggests that comorbidities between neuropsychiatric conditions and metabolic syndrome may precede and even exacerbate long-term side-effects of psychiatric medication, such as a higher risk of type 2 diabetes and cardiovascular disease, which result in increased mortality. In the present study we compare the expression of key metabolic proteins, including the insulin receptor (CD220), glucose transporter 1 (GLUT1) and fatty acid translocase (CD36), on peripheral blood mononuclear cell subtypes from patients across the neuropsychiatric spectrum, including schizophrenia, bipolar disorder, major depression and autism spectrum conditions (n = 25/condition), relative to typical controls (n = 100). This revealed alterations in the expression of these proteins that were specific to schizophrenia. Further characterization of metabolic alterations in an extended cohort of first-onset antipsychotic drug-naïve schizophrenia patients (n = 58) and controls (n = 63) revealed that the relationship between insulin receptor expression in monocytes and physiological insulin sensitivity was disrupted in schizophrenia and that altered expression of the insulin receptor was associated with whole genome polygenic risk scores for schizophrenia. Finally, longitudinal follow-up of the schizophrenia patients over the course of antipsychotic drug treatment revealed that peripheral metabolic markers predicted changes in psychopathology and the principal side effect of weight gain at clinically relevant time points. These findings suggest that peripheral blood cells can provide an accessible surrogate model for metabolic alterations in schizophrenia and have the potential to stratify subgroups of patients with different clinical outcomes or a greater risk of developing metabolic complications following antipsychotic therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbi.2020.07.043DOI Listing
January 2021

Publication Analysis

Top Keywords

peripheral blood
12
insulin receptor
12
schizophrenia patients
8
blood mononuclear
8
neuropsychiatric spectrum
8
metabolic syndrome
8
metabolic alterations
8
schizophrenia
7
metabolic
7
n = 63 revealed
4
revealed relationship
4
relationship insulin
4
receptor expression
4
controls n = 63
4
n = 58 controls
4
including schizophrenia
4
antipsychotic drug-naïve
4
patients n = 58
4
expression monocytes
4
drug-naïve schizophrenia
4

Similar Publications

[Metabolic side effects of risperidone in early onset schizophrenia].

Encephale 2010 Jun 1;36(3):242-52. Epub 2009 Dec 1.

Service de psychiatrie de l'enfant et de l'adolescent (Pr Pierre Delion), pôle régional des troubles du développement (neuropédiatrie, pédopsychiatrie), CHU de Lille, 59037 Lille, France.

Background: Atypical antipsychotics have a favourable risk/benefit profile in early onset schizophrenia (EOS). However, despite increasing use of psychotropic medication in children and adolescents, their endocrine and metabolic side-effects (weight gain, obesity, and related metabolic abnormalities such as hyperglycaemia and dyslipidemia) are of particular concern, especially within this paediatric population that appears to be at greater risk as compared with adults for antipsychotic-induced metabolic adverse effects. In addition to medication, many factors contribute to weigh gain in psychiatric patients, including sedentary lifestyle and poor diet. Read More

View Article and Full-Text PDF
June 2010

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Encephale 2009 Sep 9;35(4):330-9. Epub 2009 Jul 9.

Service des spécialités, l'Association nationale pour la promotion des soins somatiques en santé mentale, EPS Ville-Evrard, 202, avenue Jean-Jaurès, 93332 Neuilly-sur-Marne cedex, France.

Introduction: Having a mental illness has been and remains even now, a strong barrier to effective medical care. Most mental illness, such as schizophrenia, bipolar disorder, and depression are associated with undue medical morbidity and mortality. It represents a major health problem, with a 15 to 30 year shorter lifetime compared with the general population. Read More

View Article and Full-Text PDF
September 2009

Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients.

Mol Psychiatry 2011 Aug 29;16(8):848-59. Epub 2010 Jun 29.

Institute of Biotechnology, University of Cambridge, Cambridge, UK.

Little is known about the biological mechanisms underpinning the pathology of schizophrenia. We have analysed the proteome of stimulated and unstimulated peripheral blood mononuclear cells (PBMCs) from schizophrenia patients and controls as a potential model of altered cellular signaling using liquid-chromatography mass spectrometry proteomic profiling. PBMCs from patients and controls were stimulated for 72 h in vitro using staphylococcal enterotoxin B. Read More

View Article and Full-Text PDF
August 2011

Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months.

Schizophr Res 2019 04 30;206:171-176. Epub 2018 Nov 30.

Department of Psychiatry, Stellenbosch University, South Africa.

Background: Treatment-emergent weight gain is associated with antipsychotic efficacy in schizophrenia patients treated with clozapine and olanzapine. However, few studies have investigated this relationship in first-episode patients treated with other antipsychotics, in particular those with a lower obesogenic potential. Aim To investigate the relationships between weight gain and associated metabolic changes with psychopathology improvement in relation to age, sex, ethnicity, substance use, treatment duration and antipsychotic dose in first-episode schizophrenia spectrum disorder patients. Read More

View Article and Full-Text PDF
April 2019